On June 17, 2019, Lieff Cabraser and co-counsel filed a Consolidated Amended Class Action Complaint in the consumer fraud litigation against Teva, Major Pharmaceuticals, and Solco Healthcare based on reports that huge amounts of the hypertension drug Valsartan, the generic equivalent of the hypertension drug Diovan, were contaminated with a carcinogen called NDMA. This contamination and the subsequent sale and marketing of the tainted Valsartan perpetrated fraud and violation of warranties on the patient population for Valsartan, as well as violating other laws relating to the safe sale and distribution of prescription drugs.

Lieff Cabraser partner Rachel Geman serves on the Plaintiffs’ Steering Committee in the Valsartan litigation, which seeks compensation for plaintiffs’ losses and injuries relating to defendants’ negligence, failure to exercise due care in the manufacturing, testing, distribution, labeling, and marketing of, warnings and disclosures about, and sale of Valsartan throughout the United States.

Learn more about the Valsartan contamination consumer fraud litigation.

Back to blog

Contact us

Use the form below to contact a lawyer at Lieff Cabraser.

    How did you find our site?

    Okay to text me yesno
    I already have a lawyer yesno